RDUS Tiesioginiai signalai | Didinkite pelną su Getagraph.com

PARDAVIMAS 110039 min ago

@ $24.14

Išleistas: 14 vas. 2024 @ 19:18

Grąža: -27.84%

Ankstesnis signalas: vas. 12 - 22:20

Ankstesnis signalas: Pirkimas

Grąža: -4.60 %

Live Chart Being Loaded With Signals

Commentary (30 bal. 2024 @ 23:00):

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology...

Stats
Šios dienos apimtis	283 615
Vidutinė apimtis	247 201
Rinkos kapitalizacija	489.75M
EPS	$0 ( 2024-04-03 )
Last Dividend	$0.188 ( 2023-11-10 )
Next Dividend	$0 ( N/A )
P/E	-11.34
ATR14	$0.0280 (0.16%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Kelley Erika K.	Buy	0
2024-02-20	Minor Glenda J	Buy	95	Class A Common Stock
2024-02-20	Sutherlin Michael W	Buy	406	Class A Common Stock
2024-02-20	Shoemaker Leslie L	Buy	43	Class A Common Stock
2024-02-20	Jahnke David L	Buy	515	Class A Common Stock

INSIDER POWER
-79.24
Last 94 transactions
Buy: 7 552 389 \| Sell: 18 343 130

Tūris Koreliacija

Ilgas: -0.07 (neutral)

Trumpas: -0.24 (neutral)

Signal:(42.91) Neutral

Radius Health Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
COUP	0.943
APR	0.931
ICON	0.929
FTDR	0.921
ASTL	0.92
DFH	0.918
CRVL	0.917
KIN	0.915
CLBT	0.904
RMRM	0.902

10 Labiausiai neigiamai susiję koreliacijos
ORRF	-0.913
SABS	-0.913
MMAC	-0.908
LUCD	-0.908
VIEW	-0.905
AMRB	-0.89
SGMA	-0.887
LCAP	-0.885
LGHL	-0.884
TRIT	-0.883

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Radius Health Inc Koreliacija - Valiuta/Žaliavos

0.03
( neutral )

-0.03
( neutral )

0.00
( neutral )

-0.05
( neutral )

-0.40
( neutral )

0.37
( neutral )

Radius Health Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$2.88B
Bruto pelnas:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2023
Pajamos:	$2.88B
Bruto pelnas:	$307.71M (10.68 %)
EPS:	$-0.920

FY	2022
Pajamos:	$3.49B
Bruto pelnas:	$488.07M (14.00 %)
EPS:	$6.01

FY	2021
Pajamos:	$229.97M
Bruto pelnas:	$210.82M (91.67 %)
EPS:	$-1.484

Financial Reports:

No articles found.

Radius Health Inc Dividends

(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0.188 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Radius Health Inc Dividend Information - Dividend Knight

Dividend Sustainability Score: 8.22 - good (82.18%) | Divividend Growth Potential Score: 4.49 - Stable (10.28%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	$0.188	2023-04-21
Last Dividend	$0.188	2023-11-10
Next Dividend	$0	N/A
Payout Date	2023-11-27
Next Payout Date	N/A
# dividends	3	--
Total Paid Out	$0.563	--
Avg. Dividend % Per Year	0.60%	--
Score	3.68	--
Div. Sustainability Score	8.22
Div.Growth Potential Score	4.49
Div. Directional Score	6.35	--

Next Divdend (Est)
(2024-07-01)

$0.188 Estimate 22.50 %

Dividend Stability

0.60 Above Average

Dividend Score

3.68

Pay Frequency

Quarterly

Yearly Payout

Year	Amount	Yield
2023	$0.564	1.80%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.00339	1.500	9.93	10.00	[0 - 0.5]
returnOnAssetsTTM	0.00556	1.200	9.81	10.00	[0 - 0.3]
returnOnEquityTTM	0.0111	1.500	-0.988	-1.482	[0.1 - 1]
payoutRatioTTM	2.04	-1.000	10.00	-10.00	[0 - 1]
currentRatioTTM	1.927	0.800	5.36	4.29	[1 - 3]
quickRatioTTM	0.883	0.800	9.51	7.61	[0.8 - 2.5]
cashRatioTTM	0.0132	1.500	-1.038	-1.557	[0.2 - 2]
debtRatioTTM	0.251	-1.500	5.81	-8.71	[0 - 0.6]
interestCoverageTTM	2.18	1.000	-0.303	-0.303	[3 - 30]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
freeCashFlowPerShareTTM	1.095	2.00	9.45	10.00	[0 - 20]
debtEquityRatioTTM	0.501	-1.500	7.99	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.0989	1.000	-1.685	-1.685	[0.2 - 0.8]
operatingProfitMarginTTM	0.0117	1.000	-1.766	-1.766	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.392	1.000	8.93	8.93	[0.2 - 2]
assetTurnoverTTM	1.639	0.800	2.41	1.926	[0.5 - 2]
Total Score				8.22

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	48.74	1.000	5.18	0	[1 - 100]
returnOnEquityTTM	0.0111	2.50	-0.635	-1.482	[0.1 - 1.5]
freeCashFlowPerShareTTM	1.095	2.00	9.64	10.00	[0 - 30]
dividendYielPercentageTTM	4.17	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	6.55	2.00	7.82	10.00	[0 - 30]
payoutRatioTTM	2.04	1.500	10.00	-10.00	[0 - 1]
pegRatioTTM	1.774	1.500	1.509	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0602	1.000	-0.994	0	[0.1 - 0.5]
Total Score				4.49

Radius Health Inc

Radius Health, Inc., a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company's commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Teijin Limited; Berlin-Chemie AG; Eisai Co. Ltd.; and Duke University. Radius Health, Inc. was founded in 2003 and is headquartered in Boston, Massachusetts. As of August 10, 2022, Radius Health, Inc. was taken private.